** Biotech firm Argenica Therapeutics shares AGN.AX fall 10.8% to A$0.7, lowest level since May 1
** Stock poised for weakest session since early April, if trends sustain
** U.S. FDA holds co's Investigational New Drug Application, finding its data "inadequate" for clinical trials of acute ischaemic stroke $(AIS.AU)$ drug
** Co says it will provide additional data to the FDA
** AIS patients suffer from decreased blood flow to the brain
** Trading volume at more than 113,000 shares vs 30-day avg of around 100,000 shares
** Stock up 11.1% YTD, including current session's moves
(Reporting by Nikita Maria Jino in Bengaluru)
((Nikita.Jino@thomsonreuters.com;))